iGATE says new data management tech will change R&D

By Natalie Morrison

- Last updated on GMT

Pharmaceutical data managament: iGATE
iGATE says its new information management platform will provide a 70 per cent decrease in content management costs for the drug development process.

The tech – named the Research Accelorator (RA) – works from end-to-end, from data capture to management, product registrations, document and submission management, pharma co-vigilence risk management, reporting and analytics, and portfolio management.

The firm says because the entire trial is run under one do-it-all programme the process is less confusing and more streamlined, and hence less costly.

Speaking to Outsourcing-Pharma.com, associate VP Roy Devine said: “The Research Accelerator provides streamlined management of R&D data and can effectively replace the 300 or more applications currently utilized by most large pharma companies.

“It is also modular, so companies can derive benefits from the platform while leveraging their existing investments.”

Devine went on to brand the tech “transformative,” ​adding that it not only fits with the current changing trends in the industry, but also that it has the ability to change how R&D (research and development) will be conducted in the future.

“Changes in international regulations and an increasing focus on social media in the sector will prompt dramatic changes,”​ he said.

“The Research Accelerator platform and iGATE’s outcomes-based business model were strategically designed and implemented, respectively, with these developments in mind.”

As for new customers, the firm is open to any pharmaceutical company or CRO (contract research organisation) conducting clinical trials.

Devine added: “New customers do not need to completely overhaul their existing internal systems to gain benefit from the Research Accelerator as all that is necessary to gain value is to integrate the platform into their current operation over time.”

No win, no fee

Divine also that though the recent focus on “collaboration and mutual success”​ is novel now, it will no doubt be “the norm”​ in future, and said that iGATE’s outcome-based business model – which means payment is based on a specified result – reflects this.

“This ‘pay for results only’ formula enables customers to scale up and scale down based on business cycles, reduce technology risks, receive predictable results, benefit from a variable costs structure and eliminate management headaches from managing the outsourcing relationships,”​ he added.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers